WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2023)
Top diagnostic & research stocks in 2023 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Performance Score
Market Cap
Revenue
EBITDA
Earnings
EPS
Revenue Growth Y/Y
Revenue Growth 5Y
Earnings Growth Y/Y
Earnings Growth 5Y
Earnings Date
SENS
SENSEONICS HOLDINGS INC
$355.11M$18.04M$76.54M$56.73M$0.1135.57%15.53%37.50%N/A
DXCM
DEXCOM INC
$47.51B$3.02B$560.80M$292.50M$0.7617.50%31.78%13.43%N/A2023-07-26
A
AGILENT TECHNOLOGIES INC
$34.92B$7.04B$2.02B$1.35B$4.557.86%8.32%8.59%43.41%
MEDP
MEDPACE HOLDINGS INC
$6.47B$1.56B$348.81M$256.95M$8.1828.83%25.98%46.07%46.80%2023-07-24
SYNH
SYNEOS HEALTH INC
$4.31B$5.41B$525.89M$148.17M$1.451.37%10.09%-38.03%N/A2023-07-31
RVTY
REVVITY INC
$14.45B$3.36B$1.58B$961.69M$7.62-17.73%7.06%23.50%24.38%2023-07-31
QDEL
QUIDELORTHO CORP
$5.74B$3.11B$667.72M$117.60M$1.3833.72%52.81%-94.23%35.69%2023-08-03
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$10.27B$4.09B$1.03B$496.34M$9.7612.73%16.51%16.47%29.11%2023-08-01
DGX
QUEST DIAGNOSTICS INC
$15.18B$9.60B$1.59B$793.00M$6.93-10.08%5.15%-54.85%3.84%2023-07-19
QGEN
QIAGEN NV
$10.60B$2.00B$692.60M$352.93M$1.54-13.59%6.58%-34.75%43.85%2023-07-25
TWST
TWIST BIOSCIENCE CORP
$932.07M$227.84M-$170.87M-$212.61M-$3.7539.68%N/AN/AN/A2023-08-03
TMO
THERMO FISHER SCIENTIFIC INC
$200.63B$43.81B$10.74B$6.02B$15.446.53%14.76%-20.21%22.14%2023-07-26
ICLR
ICON PLC
$18.14B$7.82B$1.42B$509.99M$6.2519.83%32.06%135.85%3.24%2023-07-26
LH
LABORATORY CORP OF AMERICA HOLDINGS
$19.22B$14.76B$2.24B$1.00B$11.17-6.96%6.55%-49.18%-1.26%2023-07-26
WAT
WATERS CORP
$15.28B$2.97B$997.42M$688.85M$11.553.42%4.84%0.35%101.23%2023-07-31
DHR
DANAHER CORP
$173.13B$30.95B$10.43B$6.85B$9.412.20%14.09%7.05%20.79%2023-07-19
DMTK
DERMTECH INC
$79.28M$14.28M-$112.52M-$117.85M-$3.909.55%N/AN/AN/A
BWAY
BRAINSWAY LTD
$28.44M$25.83M-$13.40M-$13.79M-$0.80-18.01%N/AN/AN/A
NEOG
NEOGEN CORP
$4.00B$720.73M$93.02M-$13.48M$0.0440.09%13.34%-91.30%-41.12%2023-07-24
OLK
OLINK HOLDING AB (PUBL)
$2.37B$144.63M-$617.00k-$14.64M-$0.1239.04%N/AN/AN/A
MXCT
MAXCYTE INC
$450.33M$41.25M-$27.09M-$30.38M-$0.305.81%N/AN/AN/A
DRIO
DARIOHEALTH CORP
$105.71M$26.66M-$54.20M-$60.29M-$2.346.75%35.12%N/AN/A
CODX
CO-DIAGNOSTICS INC
$32.99M$12.12M-$38.58M-$31.71M-$1.01-87.95%270.52%N/AN/A
SERA
SERA PROGNOSTICS INC
$100.92M$330.00k-$41.05M-$42.54M-$1.38208.41%N/AN/AN/A
CDNA
CAREDX INC
$437.34M$319.64M-$69.20M-$80.71M-$1.523.64%44.47%N/AN/A2023-08-02
BNR
BURNING ROCK BIOTECH LTD
$251.46M$82.05MN/A-$128.79M-$1.25-1.03%N/AN/AN/A2023-08-02
XGN
EXAGEN INC
$51.99M$46.40M-$39.79M-$44.80M-$2.60-3.55%N/AN/AN/A2023-08-02
CHEK
CHECK-CAP LTD
$10.41M$0.00-$18.58M-$17.72M-$3.00N/AN/AN/AN/A2023-08-01
IDXX
IDEXX LABORATORIES INC
$39.08B$3.43B$1.05B$699.18M$8.404.79%10.91%-2.89%20.99%2023-07-31
BNGO
BIONANO GENOMICS INC
$243.59M$29.52M-$126.44M-$139.77M-$0.4743.94%N/AN/AN/A2023-08-02
BVS
BIOVENTUS INC
$231.69M$513.89M-$224.26M-$286.58M-$4.6310.18%N/AN/AN/A
ME
23ANDME HOLDING CO
$945.57M$299.49M-$277.93M-$311.66M-$0.6910.15%-7.44%N/AN/A
STIM
NEURONETICS INC
$77.24M$66.57M-$30.47M-$36.84M-$1.3516.36%9.10%N/AN/A2023-07-31
CSTL
CASTLE BIOSCIENCES INC
$606.69M$152.22M-$62.30M-$71.72M-$2.7255.13%N/AN/AN/A
MTD
METTLER TOLEDO INTERNATIONAL INC
$29.35B$3.95B$1.26B$886.93M$39.683.66%7.19%15.08%21.95%2023-07-27
MOTS
MOTUS GI HOLDINGS INC
$3.33M$628.00k-$16.19M-$18.17M-$4.8174.44%120.68%N/AN/A
OPK
OPKO HEALTH INC
$1.12B$912.55M-$212.17M-$291.24M-$0.39-41.46%-0.90%N/AN/A2023-08-02
ANIX
ANIXA BIOSCIENCES INC
$102.98M$0.00-$12.05M-$12.09M-$0.41N/A-100.00%N/AN/A2023-06-09
NRC
NATIONAL RESEARCH CORP
$1.12B$149.60M$46.88M$30.23M$1.22-0.88%4.81%-15.86%16.85%2023-08-01
RNLX
RENALYTIX PLC
$89.12M$3.80M-$41.65M-$42.25M-$1.1257.32%N/AN/AN/A2023-06-13
PSNL
PERSONALIS INC
$96.37M$68.68M-$101.20M-$113.77M-$2.46-13.98%N/AN/AN/A2023-08-01
ILMN
ILLUMINA INC
$32.78B$4.45B-$4.10B-$4.49B-$28.51-4.49%8.67%N/AN/A
FLGT
FULGENT GENETICS INC
$1.20B$364.87M$3.41M-$25.92M-$0.85-61.73%82.39%N/AN/A2023-08-02
LNTH
LANTHEUS HOLDINGS INC
$6.06B$1.03B$19.14M-$17.70M-$0.2689.62%25.29%N/AN/A2023-08-02
GENE
GENETIC TECHNOLOGIES LTD
$17.58M$6.14M-$6.11M-$6.00M-$0.41287.92%98.64%N/AN/A
NTRA
NATERA INC
$5.58B$867.85M-$501.98M-$546.14M-$5.3530.05%31.28%N/AN/A2023-08-02
IQV
IQVIA HOLDINGS INC
$37.36B$14.49B$2.91B$1.06B$5.673.29%7.91%0.35%-0.28%2023-07-19
CELC
CELCUITY INC
$242.86M$0.00-$41.26M-$44.37M-$2.66N/AN/AN/AN/A
ONVO
ORGANOVO HOLDINGS INC
$14.99M$1.71M-$11.43M-$11.71M-$1.34N/A-16.90%N/AN/A
GH
GUARDANT HEALTH INC
$3.33B$482.15M-$600.17M-$664.89M-$6.5023.29%N/AN/AN/A2023-08-02
HSKA
HESKA CORP
$1.31B$254.89M-$6.06M-$20.03M-$1.92-1.22%13.97%N/AN/A
LMDX
LUMIRADX LTD
$129.07M$150.24M-$276.90M-$435.75M-$1.50-65.93%N/AN/AN/A
NEO
NEOGENOMICS INC
$2.29B$529.78M-$61.34M-$125.64M-$1.019.02%16.56%N/AN/A
SRDX
SURMODICS INC
$268.83M$102.97M-$18.00M-$35.96M-$2.586.21%6.85%N/AN/A2023-07-25
PACB
PACIFIC BIOSCIENCES OF CALIFORNIA INC
$3.37B$134.03M-$288.50M-$320.76M-$1.39-0.49%8.80%N/AN/A2023-08-01
PRPO
PRECIPIO INC
$14.46M$9.78M-$9.11M-$10.64M-$0.463.27%34.93%N/AN/A
PMD
PSYCHEMEDICS CORP
$27.18M$24.59M$1.54M-$1.51M-$0.27-4.33%-9.46%N/AN/A
EXAS
EXACT SCIENCES CORP
$15.12B$2.20B-$283.33M-$516.72M-$2.9218.83%48.18%N/AN/A2023-07-31
MYGN
MYRIAD GENETICS INC
$1.91B$694.70M-$93.40M-$146.20M-$1.801.80%-0.37%N/AN/A2023-08-02
PRE
PRENETICS GLOBAL LTD
$120.55M$275.76M-$175.76M-$190.45M-$2.50-0.03%N/AN/AN/A2023-06-05
BDSX
BIODESIX INC
$105.92M$40.72M-$53.04M-$68.56M-$1.3126.51%N/AN/AN/A2023-08-02
GTH
GENETRON HOLDINGS LTD
$80.65M$94.31M-$101.00M-$117.16M-$1.2612.32%43.63%N/AN/A
AXDX
ACCELERATE DIAGNOSTICS INC
$74.87M$12.61M-$58.43M-$65.82M-$0.733.14%23.17%N/AN/A
OABI
OMNIAB INC
$502.86M$66.37MN/A-$22.15MN/A80.53%N/AN/AN/A
VRAX
VIRAX BIOLABS GROUP LTD
$4.61M$5.76k-$2.59M-$2.60M-$0.81-94.76%N/AN/AN/A
BMRA
BIOMERICA INC
$21.20M$9.53M-$6.49M-$7.11M-$0.54-34.81%10.13%N/AN/A
BIAF
BIOAFFINITY TECHNOLOGIES INC
$15.25M$5.72k-$6.82M-$8.21M-$1.16N/AN/AN/AN/A
NDRA
ENDRA LIFE SCIENCES INC
$11.22M$0.00-$13.01M-$13.26M-$4.09N/A-100.00%N/AN/A
BIOC
BIOCEPT INC
$1.26M$11.38M-$30.06M-$32.23M-$56.70-82.06%22.10%N/AN/A
AWH
ASPIRA WOMEN's HEALTH INC
$25.00M$8.61M-$23.76M-$23.97M-$2.9819.39%23.11%N/AN/A
SQL
SEQLL INC
$6.42M$31.18k-$4.59M-$4.88M-$0.39-84.15%N/AN/AN/A
LAB
STANDARD BIOTOOLS INC
$185.77M$96.56M-$124.87M-$130.65M-$1.66-22.31%-1.02%N/AN/A
AKU
AKUMIN INC
$34.39M$750.96M$64.12M-$161.10M-$1.7938.20%N/AN/AN/A
NOTV
INOTIV INC
$154.30M$597.35M-$274.88M-$345.20M-$13.91115.27%91.77%N/AN/A
OPGN
OPGEN INC
$4.28M$3.05M-$32.13M-$36.22M-$13.72-22.68%-1.47%N/AN/A
ISPC
ISPECIMEN INC
$12.10M$10.83M-$10.03M-$10.29M-$1.161.34%N/AN/AN/A
TTOO
T2 BIOSYSTEMS INC
$2.54M$17.15M-$55.25M-$63.80M-$9.41-39.48%23.22%N/AN/A
SHC
SOTERA HEALTH CO
$4.17B$987.52M-$35.32M-$261.37M-$0.933.29%N/AN/AN/A2023-08-02
ENZ
ENZO BIOCHEM INC
$109.75M$81.12M-$32.58M-$35.24M-$0.73-31.36%-5.13%N/AN/A2023-06-07
HTGM
HTG MOLECULAR DIAGNOSTICS INC
$4.69M$6.21M-$18.48M-$20.15M-$17.80-28.21%-18.75%N/AN/A
CNTG
CENTOGENE NV
$24.84M$52.17M-$18.16M-$35.07M-$1.595.23%5.83%N/AN/A2023-07-13
VNRX
VOLITIONRX LTD
$97.30M$341.99k-$30.00M-$31.41M-$0.5691.36%N/AN/AN/A
SLNO
SOLENO THERAPEUTICS INC
$48.60M$0.00-$24.44M-$26.70M-$2.81N/AN/AN/AN/A
PHG
KONINKLIJKE PHILIPS NV
$17.16B$19.17B$149.46M-$1.73B-$1.96-2.72%-2.34%N/AN/A2023-07-24
CDIO
CARDIO DIAGNOSTICS HOLDINGS INC
$13.87M$950.00N/A-$5.40M-$1.305.44%N/AN/AN/A
RDNT
RADNET INC
$1.77B$1.48B$238.42M-$13.37M-$0.2310.24%9.85%N/AN/A
NVTA
INVITAE CORP
$278.92M$509.97M-$2.91B-$3.12B-$13.186.13%42.91%N/AN/A
MDXH
MDXHEALTH SA
$108.96MN/AN/AN/AN/AN/AN/AN/AN/A
MYNZ
MAINZ BIOMED NV
$84.70MN/AN/AN/AN/AN/AN/AN/AN/A
TRIB
TRINITY BIOTECH PLC
$37.35M$74.78M-$14.12M-$41.01M-$1.20-19.56%-5.48%N/AN/A2023-07-20

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Jun 2023?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Senseonics Holdings (NYSEMKT:SENS)


Senseonics Holdings (NYSEMKT:SENS) is the top diagnostic & research stock with a Zen Score of 58, which is 30 points higher than the diagnostic & research industry average of 28. It passed 19 out of 33 due diligence checks and has strong fundamentals. Senseonics Holdings has seen its stock lose -37.29% over the past year, underperforming other diagnostic & research stocks by -32 percentage points.

Senseonics Holdings has an average 1 year price target of $3.00, an upside of 305.41% from Senseonics Holdings's current stock price of $0.74.

Senseonics Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Senseonics Holdings, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Dexcom (NASDAQ:DXCM)


Dexcom (NASDAQ:DXCM) is the second best diagnostic & research stock with a Zen Score of 52, which is 24 points higher than the diagnostic & research industry average of 28. It passed 18 out of 33 due diligence checks and has strong fundamentals. Dexcom has seen its stock return 57.23% over the past year, overperforming other diagnostic & research stocks by 63 percentage points.

Dexcom has an average 1 year price target of $132.73, an upside of 8.29% from Dexcom's current stock price of $122.57.

Dexcom stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Dexcom, 54.55% have issued a Strong Buy rating, 18.18% have issued a Buy, 27.27% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Agilent Technologies (NYSE:A)


Agilent Technologies (NYSE:A) is the third best diagnostic & research stock with a Zen Score of 47, which is 19 points higher than the diagnostic & research industry average of 28. It passed 18 out of 38 due diligence checks and has strong fundamentals. Agilent Technologies has seen its stock lose -8.43% over the past year, underperforming other diagnostic & research stocks by -3 percentage points.

Agilent Technologies has an average 1 year price target of $145.42, an upside of 23.01% from Agilent Technologies's current stock price of $118.22.

Agilent Technologies stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Agilent Technologies, 33.33% have issued a Strong Buy rating, 41.67% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 9 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Koninklijke Philips Nv (NYSE:PHG)


Koninklijke Philips Nv (NYSE:PHG) has an annual dividend yield of N/A, which is N/A percentage points lower than the diagnostic & research industry average of 1.55%. Koninklijke Philips Nv's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. Koninklijke Philips Nv's dividend has not shown consistent growth over the last 10 years.

Koninklijke Philips Nv's dividend payout ratio of -49.3% indicates that its dividend yield might not be sustainable for the long-term.

2. Psychemedics (NASDAQ:PMD)


Psychemedics (NASDAQ:PMD) has an annual dividend yield of 5.89%, which is 4 percentage points higher than the diagnostic & research industry average of 1.55%. Psychemedics's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Psychemedics's dividend has not shown consistent growth over the last 10 years.

Psychemedics's dividend payout ratio of -103.7% indicates that its high dividend yield might not be sustainable for the long-term.

3. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.98%, which is the same as the diagnostic & research industry average of 1.55%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.8% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 1.04% in the last day, and up 1.06% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are up.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Syneos Health (NASDAQ:SYNH)


Syneos Health (NASDAQ:SYNH) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Syneos Health has a valuation score of 86, which is 58 points higher than the diagnostic & research industry average of 28. It passed 6 out of 7 valuation due diligence checks.

Syneos Health's stock has dropped -44.25% in the past year. It has underperformed other stocks in the diagnostic & research industry by -39 percentage points.

2. Laboratory Of America Holdings (NYSE:LH)


Laboratory Of America Holdings (NYSE:LH) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Laboratory Of America Holdings has a valuation score of 71, which is 43 points higher than the diagnostic & research industry average of 28. It passed 5 out of 7 valuation due diligence checks.

Laboratory Of America Holdings's stock has dropped -12.79% in the past year. It has underperformed other stocks in the diagnostic & research industry by -7 percentage points.

3. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Icon has a valuation score of 57, which is 29 points higher than the diagnostic & research industry average of 28. It passed 4 out of 7 valuation due diligence checks.

Icon's stock has dropped -1.34% in the past year. It has overperformed other stocks in the diagnostic & research industry by 4 percentage points.

Are diagnostic & research stocks a good buy now?

49.25% of diagnostic & research stocks rated by analysts are a buy right now. On average, analysts expect diagnostic & research stocks to rise by 21.44% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 31.67x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.